Syros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Below 50-Day Moving Average of $6.38

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $6.38 and traded as low as $5.18. Syros Pharmaceuticals shares last traded at $5.56, with a volume of 287,306 shares.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SYRS. Piper Sandler reiterated an “overweight” rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Syros Pharmaceuticals in a research note on Monday, April 1st. Finally, StockNews.com downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday.

Syros Pharmaceuticals Stock Down 7.6 %

The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. The stock has a market cap of $126.17 million, a price-to-earnings ratio of -0.82 and a beta of 1.74. The firm’s 50-day simple moving average is $6.29 and its two-hundred day simple moving average is $5.18.

Institutional Investors Weigh In On Syros Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Two Sigma Investments LP acquired a new stake in shares of Syros Pharmaceuticals during the 4th quarter worth approximately $38,000. Price T Rowe Associates Inc. MD acquired a new position in Syros Pharmaceuticals during the fourth quarter valued at approximately $44,000. Virtu Financial LLC acquired a new position in Syros Pharmaceuticals during the fourth quarter valued at approximately $45,000. HighTower Advisors LLC acquired a new position in Syros Pharmaceuticals during the fourth quarter valued at approximately $53,000. Finally, CIBC Asset Management Inc acquired a new position in Syros Pharmaceuticals during the first quarter valued at approximately $41,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.